Financial Performance - Cash, cash equivalents, and investments totaled $294.9 million as of December 31, 2024, up from $203.0 million as of December 31, 2023, providing a cash runway into the second half of 2027[5] - Net loss for Q4 2024 was $22.2 million, resulting in a basic and diluted net loss per share of $0.86, compared to a net loss of $12.9 million and a loss per share of $0.81 in Q4 2023[12] - Tourmaline's total operating expenses for the full year 2024 were $89.7 million, compared to $45.4 million in 2023[16] - The increase in net loss for both periods was primarily due to increased operating expenses and overall growth during 2024[12] Research and Development - Research and development expenses for Q4 2024 were $20.5 million, compared to $8.0 million in Q4 2023, and for the full year 2024, they were $67.0 million, up from $32.4 million in 2023[12] - The Phase 2 TRANQUILITY trial has over-enrolled to 143 participants, exceeding the initial target of 120, with topline data expected in Q2 2025[3] - The company anticipates topline data from the Phase 2b spiriTED trial in the second half of 2025, focusing on thyroid eye disease[6] - Tourmaline plans to provide additional details on a Phase 2 proof-of-concept trial for abdominal aortic aneurysm after the TRANQUILITY trial results[3] Company Growth and Assets - Tourmaline's total assets increased to $309.0 million as of December 31, 2024, from $210.3 million in 2023[18] - The company has strengthened its Cardiovascular Scientific Advisory Board with the addition of prominent experts in the field[6]
TALARIS THERAPEU(TALS) - 2024 Q4 - Annual Results